chevron_leftBack
As of 13 June 2026, DiaMedica Therapeutics Inc. has a market cap of $321.14M USD, ranking #18176 globally and #3028 in the United States.
It ranks #1650 in the Healthcare sector, and #315 in the Biotechnology industry.
Key Stats
Market Cap
$321.14MUSD
Enterprise Value
$262.57MUSD
EBITDA (TTM)
-$34.35MUSD
Net Income (TTM)
-$32.77MUSD
PB Ratio
6.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Dietrich Pauls
open_in_new
Employees
35
Founded
2000
Website
diamedica.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -4.2% | -7.9% | -12% | -29% | -12% | 28% |
News
Loading...
DMAC Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
DMAC
DiaMedica Therapeutics Inc
ISIN: CA25253X2077
Shares Out.:
Shares Outstanding:
53.883M1
Shares Float:
27.065M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
5.96 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NASDAQ: AMGN
|
$182.42B
57K%
|
23.9
|
|
NASDAQ: GILD
|
$159.92B
50K%
|
19.0
|
|
NASDAQ: NTRA
|
$27.6B
8K%
|
-
|
|
NYSE: IQV
|
$26.3B
8K%
|
20.0
|
|
NASDAQ: UTHR
|
$25.03B
8K%
|
20.4
|
|
NASDAQ: MRNA
|
$18.13B
6K%
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
EBR: ARGX
|
$47.84B
15K%
41.39B EUR
|
39.9
|
|
KRX: 207940
|
$44.84B
14K%
68.19T KRW
|
35.5
|
|
ASX: CSL
|
$42.36B
13K%
60.27B AUD
|
29.3
|
|
SIX: LONN
|
$42.3B
13K%
33.71B CHF
|
37.2
|
|
KRX: 068270
|
$28.11B
9K%
42.76T KRW
|
43.8
|
|
NASDAQ: BNTX
|
$25.69B
8K%
|
-
|
chevron_leftBack